Canada


Year
October 27, 2014
Mississauga, ON - October 27, 2014 - Genzyme, a Sanofi company, announces that Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) have be included on the provincial drug formulary under “Médicaments d’exception”.
February 27, 2014
Mississauga, ON – February 27, 2014 – Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Last Updated: 12/3/2015
Contact

Genzyme Canada
Canadian Office 
2700 Matheson Blvd. East 
West Tower, Suite 800 
Mississauga, Ontario L4W 4V9 
Canada 
Tel: +1 905 625 0011 
Fax: +1 905 625 7811 
Toll Free: +1 877 220 8918 
Email

Genzyme Medical Information 
Tel: +1 800 589 6215
Email

If this is an emergency, please contact your local emergency department.

Ethics inquiries 
Tel: +1 800 648 1297

This Is Genzyme
Discover more about Genzyme's purpose, legacy, and innovation in our corporate brochure.

Careers
Explore opportunities at a company that's as committed to our employees as we are to our patients.

infoBox